{"disease":{"id":"third-line-treatment","name":"third line treatment"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06930118","title":"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT05426811","title":"Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"China Medical University, China","has_results":false},{"nct_id":"NCT05810142","title":"Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"RenJi Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}